|
1
|
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
|
Cell Stem Cell
|
2007
|
22.89
|
|
2
|
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
|
Cancer Res
|
2009
|
7.98
|
|
3
|
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
|
J Clin Oncol
|
2006
|
4.87
|
|
4
|
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
|
Breast Cancer Res Treat
|
2008
|
4.84
|
|
5
|
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.
|
Clin Cancer Res
|
2009
|
4.47
|
|
6
|
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
|
J Clin Oncol
|
2007
|
3.35
|
|
7
|
How basal are triple-negative breast cancers?
|
Int J Cancer
|
2008
|
3.18
|
|
8
|
Integrated profiling of basal and luminal breast cancers.
|
Cancer Res
|
2007
|
2.86
|
|
9
|
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
|
Cancer Res
|
2006
|
2.52
|
|
10
|
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.
|
J Clin Invest
|
2011
|
2.44
|
|
11
|
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
|
Cancer Res
|
2005
|
2.26
|
|
12
|
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.
|
Oncogene
|
2004
|
2.09
|
|
13
|
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.
|
Cancer Res
|
2005
|
2.05
|
|
14
|
A gene expression signature identifies two prognostic subgroups of basal breast cancer.
|
Breast Cancer Res Treat
|
2010
|
2.03
|
|
15
|
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
|
J Clin Oncol
|
2007
|
1.99
|
|
16
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
|
J Clin Oncol
|
2007
|
1.93
|
|
17
|
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
|
Lancet Oncol
|
2012
|
1.91
|
|
18
|
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.
|
Am J Pathol
|
2002
|
1.89
|
|
19
|
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
|
Breast Cancer Res Treat
|
2010
|
1.81
|
|
20
|
Prognosis and gene expression profiling of 20q13-amplified breast cancers.
|
Clin Cancer Res
|
2006
|
1.75
|
|
21
|
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
|
Blood
|
2003
|
1.62
|
|
22
|
Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
|
Cancer Res
|
2004
|
1.61
|
|
23
|
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.
|
BMC Cancer
|
2006
|
1.58
|
|
24
|
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
|
J Pathol
|
2004
|
1.53
|
|
25
|
Genome profiling of ERBB2-amplified breast cancers.
|
BMC Cancer
|
2010
|
1.53
|
|
26
|
Gene expression profiles of poor-prognosis primary breast cancer correlate with survival.
|
Hum Mol Genet
|
2002
|
1.37
|
|
27
|
Identification and validation of an ERBB2 gene expression signature in breast cancers.
|
Oncogene
|
2004
|
1.31
|
|
28
|
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
|
Clin Cancer Res
|
2013
|
1.30
|
|
29
|
Nectin-4 is a new histological and serological tumor associated marker for breast cancer.
|
BMC Cancer
|
2007
|
1.30
|
|
30
|
Recent trends in epidemiology of brain metastases: an overview.
|
Anticancer Res
|
2012
|
1.26
|
|
31
|
Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
|
Cancer Res
|
2008
|
1.26
|
|
32
|
Kinome expression profiling and prognosis of basal breast cancers.
|
Mol Cancer
|
2011
|
1.22
|
|
33
|
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
|
Blood
|
2003
|
1.22
|
|
34
|
Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
|
Eur J Pharmacol
|
2007
|
1.21
|
|
35
|
How different are luminal A and basal breast cancers?
|
Int J Cancer
|
2009
|
1.15
|
|
36
|
Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
|
Haematologica
|
2007
|
1.14
|
|
37
|
High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
|
PLoS One
|
2011
|
1.14
|
|
38
|
ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.
|
Cancer Res
|
2013
|
1.14
|
|
39
|
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
|
BMC Cancer
|
2008
|
1.13
|
|
40
|
Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
|
Stem Cells
|
2012
|
1.13
|
|
41
|
Gene expression profiling and clinical outcome in breast cancer.
|
OMICS
|
2006
|
1.10
|
|
42
|
Moesin expression is a marker of basal breast carcinomas.
|
Int J Cancer
|
2007
|
1.09
|
|
43
|
Gene expression profiling of inflammatory breast cancer.
|
Cancer
|
2010
|
1.07
|
|
44
|
Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature.
|
BMC Cancer
|
2010
|
1.05
|
|
45
|
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes.
|
Mol Cell Proteomics
|
2008
|
1.04
|
|
46
|
Loss, mutation and deregulation of L3MBTL4 in breast cancers.
|
Mol Cancer
|
2010
|
1.04
|
|
47
|
Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?
|
Eur J Cancer
|
2012
|
1.02
|
|
48
|
Defining the molecular biology of inflammatory breast cancer.
|
Semin Oncol
|
2008
|
1.02
|
|
49
|
Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.99
|
|
50
|
High-dose chemotherapy for breast cancer: the French PEGASE experience.
|
Cancer Control
|
2003
|
0.98
|
|
51
|
Comparative multi-methodological measurement of ERBB2 status in breast cancer.
|
J Pathol
|
2004
|
0.97
|
|
52
|
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
|
Mol Cancer
|
2014
|
0.96
|
|
53
|
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
|
Cancer
|
2003
|
0.95
|
|
54
|
Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer.
|
Gynecol Oncol
|
2006
|
0.94
|
|
55
|
8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer.
|
PLoS One
|
2012
|
0.94
|
|
56
|
Prognosis of breast cancer and gene expression profiling using DNA arrays.
|
Ann N Y Acad Sci
|
2002
|
0.93
|
|
57
|
Full access to medical records does not modify anxiety in cancer patients: results of a randomized study.
|
Cancer
|
2011
|
0.93
|
|
58
|
Breast cancer revisited using DNA array-based gene expression profiling.
|
Int J Cancer
|
2003
|
0.93
|
|
59
|
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
|
Breast Cancer Res
|
2011
|
0.91
|
|
60
|
Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups.
|
Clin Cancer Res
|
2012
|
0.90
|
|
61
|
Clinical development of mTOR inhibitors in breast cancer.
|
Breast Cancer Res
|
2014
|
0.89
|
|
62
|
Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate.
|
Transfusion
|
2005
|
0.87
|
|
63
|
Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome.
|
Eur J Cancer
|
2011
|
0.86
|
|
64
|
Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.
|
BMC Cancer
|
2008
|
0.86
|
|
65
|
Desmoid-type fibromatosis.
|
J Neurosurg
|
2007
|
0.85
|
|
66
|
DNA arrays in clinical oncology: promises and challenges.
|
Lab Invest
|
2003
|
0.85
|
|
67
|
Young breast cancer patients' involvement in treatment decisions: the major role played by decision-making about surgery.
|
Psychooncology
|
2013
|
0.83
|
|
68
|
Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.
|
Support Care Cancer
|
2002
|
0.83
|
|
69
|
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
|
Am J Clin Oncol
|
2009
|
0.83
|
|
70
|
Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience.
|
Int J Cancer
|
2010
|
0.83
|
|
71
|
Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients.
|
Int J Cancer
|
2009
|
0.83
|
|
72
|
[Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
|
Bull Cancer
|
2013
|
0.83
|
|
73
|
Palliation of patients with dysphagia due to advanced esophageal cancer by endoscopic injection of cisplatin/epinephrine injectable gel.
|
Gastrointest Endosc
|
2002
|
0.83
|
|
74
|
Genomic and expression analysis of microdissected inflammatory breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.82
|
|
75
|
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
|
Anticancer Res
|
2011
|
0.82
|
|
76
|
BetaHCG secretion by a pulmonary adenocarcinoma.
|
World J Surg Oncol
|
2013
|
0.82
|
|
77
|
Inflammatory breast cancers in Tunisia and France show similar immunophenotypes.
|
Breast
|
2007
|
0.81
|
|
78
|
Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
|
Int J Gynecol Cancer
|
2015
|
0.81
|
|
79
|
Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy.
|
Breast J
|
2012
|
0.80
|
|
80
|
CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Exp Hematol
|
2004
|
0.80
|
|
81
|
Gene-expression profiling and identification of patients at high risk of breast cancer.
|
Lancet
|
2002
|
0.80
|
|
82
|
Nurses' repeat measurement of chemotherapy symptoms: feasibility, resulting information, patient satisfaction.
|
Cancer Nurs
|
2003
|
0.80
|
|
83
|
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
|
Pathobiology
|
2013
|
0.80
|
|
84
|
Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Exp Hematol
|
2010
|
0.79
|
|
85
|
[Targeted chemotherapy for breast cancer: patients perception of the use of tumor gene profiling approaches to better adapt treatments].
|
Med Sci (Paris)
|
2012
|
0.79
|
|
86
|
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
|
Breast Cancer Res Treat
|
2011
|
0.79
|
|
87
|
Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.
|
Int J Cancer
|
2003
|
0.79
|
|
88
|
Assessment of prognostic scores in brain metastases from breast cancer.
|
Neuro Oncol
|
2013
|
0.79
|
|
89
|
Patients' regrets after participating in a randomized controlled trials depended on their involvement in the decision making.
|
J Clin Epidemiol
|
2012
|
0.78
|
|
90
|
[Stem cells and epithelial cancers: the example of breast cancer].
|
Ann Pathol
|
2008
|
0.78
|
|
91
|
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
|
Clin Cancer Res
|
2003
|
0.78
|
|
92
|
Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?
|
Crit Rev Oncol Hematol
|
2009
|
0.78
|
|
93
|
Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials.
|
Eur Cytokine Netw
|
2002
|
0.78
|
|
94
|
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
|
Anticancer Drugs
|
2009
|
0.78
|
|
95
|
Lung cancer in elderly patients: a retrospective analysis of practice in a single institution.
|
Crit Rev Oncol Hematol
|
2007
|
0.77
|
|
96
|
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.77
|
|
97
|
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
|
Breast Cancer Res Treat
|
2011
|
0.77
|
|
98
|
[Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers].
|
Bull Cancer
|
2010
|
0.76
|
|
99
|
[Risk of stage underestimation of breast cancer by sentinel lymph node biopsy method].
|
Bull Cancer
|
2003
|
0.76
|
|
100
|
Are there candidates for high-dose chemotherapy in ovarian carcinoma?
|
J Exp Clin Cancer Res
|
2012
|
0.76
|
|
101
|
Association of carcinoid tumor and low grade glioma.
|
World J Surg Oncol
|
2012
|
0.75
|
|
102
|
Medullary thyroid cancer treated by capecitabine.
|
Anticancer Drugs
|
2007
|
0.75
|
|
103
|
Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.
|
PLoS One
|
2012
|
0.75
|
|
104
|
A modest impact of cancer on young adult caregivers' educational plans?
|
Am J Public Health
|
2006
|
0.75
|
|
105
|
Difference in therapeutic response between basal and nonbasal triple-negative breast cancers.
|
Oncologist
|
2013
|
0.75
|
|
106
|
[Sentinel lymph node negative breast cancer larger than 30 mm: is axillary lymph node dissection constantly necessary?].
|
Bull Cancer
|
2004
|
0.75
|
|
107
|
[What is new about sentinel lymph node biopsy in breast cancer?].
|
Bull Cancer
|
2004
|
0.75
|
|
108
|
[G-CSF in oncology].
|
Bull Cancer
|
2006
|
0.75
|
|
109
|
[Prostate cancer and chemotherapy].
|
Bull Cancer
|
2007
|
0.75
|
|
110
|
Transparency in the presentation of trial results may not increase patients' trust in medical researchers.
|
Clin Trials
|
2011
|
0.75
|
|
111
|
Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors.
|
Anticancer Res
|
2013
|
0.75
|
|
112
|
[Systemic learning planification for medical students during oncology clinical rotation].
|
Bull Cancer
|
2011
|
0.75
|
|
113
|
[Inflammatory breast carcinoma: towards molecular characterization?].
|
Ann Pathol
|
2003
|
0.75
|
|
114
|
Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy.
|
Exp Hematol
|
2002
|
0.75
|
|
115
|
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
|
Breast
|
2006
|
0.75
|
|
116
|
A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.
|
Chemotherapy
|
2015
|
0.75
|
|
117
|
Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer.
|
Pharmacoeconomics
|
2003
|
0.75
|